1. Search Result
Search Result
Results for "

5-alpha Reductase Inhibitors

" in MCE Product Catalog:

17

Inhibitors & Agonists

4

Natural
Products

Cat. No. Product Name Target Research Areas
  • HY-U00376
    -reductase-IN-1

    5 alpha Reductase Metabolic Disease
    -reductase-IN-1 is an inhibitor of 5α-reductase, used for the research of patterned alopecia in combination with minoxidil.
  • HY-123349
    -Hydroxy-6-keto cholesterol

    Drug Metabolite Cardiovascular Disease
    -Hydroxy-6-keto cholesterol is major metabolite of β-epoxide (5α,6β-epoxycholesterol) during direct exposure of intact cultured human bronchial epithelial cells (16-HBE) to ozone. -Hydroxy-6-keto cholesterol inhibits cholesterol synthesis with an IC50 of 350 nM.
  • HY-13635A
    Finasteride acetate

    MK-906 acetate

    5 alpha Reductase Cancer
    Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II -reductase. Finasteride acetate has approximately a 100-fold greater affinity for type II -reductase enzyme than for the type I enzyme. Finasteride acetate can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia.
  • HY-13635
    Finasteride

    MK-906

    5 alpha Reductase Cancer
    Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II -reductase. Finasteride has approximately a 100-fold greater affinity for type II -reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia.
  • HY-118091B
    LY300503

    Others Others
    LY300503 is an enantiomer of LY191704. LY191704 is a human type I -reductase inhibitor.
  • HY-B0141A
    Alpha-Estradiol

    Alfatradiol; Epiestradiol; Epiestrol

    5 alpha Reductase Endogenous Metabolite Inflammation/Immunology
    Alpha-Estradiol is a weak estrogen and a 5α-reductase inhibitor which is used as a topical medication in the treatment of androgenic alopecia.
  • HY-N2666
    -Hydroxycostic acid

    VEGFR Cancer
    -Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. -Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating VEGF/VEGFR2 and Ang2/Tie2 pathways.
  • HY-U00125
    CGP-53153

    5 alpha Reductase Endocrinology
    CGP-53153 is a steroidal inhibitor of 5 alpha reductase with IC50s of 36 and 262 nM in rat and human prostatic tissue, respectively.
  • HY-118091
    LY191704

    5 alpha Reductase Endocrinology
    LY191704, as a benzoquinolinone, is a potent, nonsteroidal, noncompetitive and selective human type I 5α-reductase inhibitor. LY191704 is a racemic mixture of the compounds LY300502 and LY300503. LY191704 may be useful in the research of human endocrine disorders associated with overproduction of dihydrotestosterone (DHT) by -reductase type 1.
  • HY-N1200
    Stigmasterol glucoside

    5 alpha Reductase Inflammation/Immunology
    Stigmasterol glucoside is a sterol isolated from P. urinaria with high antioxidant and anti-inflammatory activities, act as an inhibitor of 5α-reductase with an IC50 of 27.2 µM.
  • HY-13613
    Dutasteride

    GG 745; GI 198745

    5 alpha Reductase Apoptosis Cancer
    Dutasteride (GG745) is a potent inhibitor of both -reductase isozymes. Dutasteride may possess off-target effects on the androgen receptor (AR) due to its structural similarity to DHT.
  • HY-103245
    Cl-4AS-1

    Androgen Receptor Cancer
    Cl-4AS-1, a potent steroidal androgen receptor (AR) agonist (IC50 = 12 nM), is also an inhibitor of -reductase types I and II (IC50 = 6 and 10 nM, respectively).
  • HY-118091A
    Bexlosteride

    LY300502

    Others Cancer
    Bexlosteride (LY300502) is a benzoquinolinone human type I -reductase inhibitor. Bexlosteride shows metabolic inhibitory, antiproliferative, and antisecretory effects in LNCaP human prostatic adenocarcinoma cell cultures. Bexlosteride can be used for the research of prostatic cancer.
  • HY-N7510
    12-O-Methylcarnosic acid

    12-Methoxycarnosic acid

    5 alpha Reductase Cancer Infection
    12-O-Methylcarnosic acid (12-Methoxycarnosic acid), a diterpene carnosic acid isolated from the acetone extract of Salvia microphylla, is an active constituent of 5α-reductase inhibition with an IC50 value of 61.7 μM. 12-O-Methylcarnosic acid inhibits proliferation in LNCaP cells. 12-O-Methylcarnosic acid has antioxidant, anti-cancer and antimicrobial activity.
  • HY-14571
    E7820

    ER68203-00

    Integrin Cancer
    E7820 (ER68203-00), an orally active aromatic sulfonamide derivative, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. E7820 inhibits rat aorta angiogenesis with an IC50 of 0.11 μg/ml. E7820 modulates α-1, α-2, α-3, and α-5 integrin mRNA expression. Antiangiogenic and antitumor activity.
  • HY-108952
    17,17-(Ethylenedioxy)androst-4-en-3-one

    Others Endocrinology
    17,17-(Ethylenedioxy)androst-4-en-3-one (4-​androstene-​3,​17-​dione-​17-​cyclic ethylene ketal) is an effective ingredient in cosmetics, which can be used for acne and promote hair growth research. 17,17-(Ethylenedioxy)androst-4-en-3-one can inhibit the reductase activity and inhibit the bond of a receptor protein and 5α-DHT.
  • HY-19306
    SB-267268

    Integrin Cancer
    SB-267268 is a selective and nonpeptidic alpha(v)beta3 (αvβ3) and alpha(v)beta5 (αvβ5) integrins antagonist, with Kis of 0.9, 0.5 and 0.7 nM for human αvβ3, monkey αvβ3 and human αvβ5, respectively. SB-267268 inhibits human and mouse αvβ3 with IC50s of 0.68 and 0.29 nM, respectively. SB-267268 reduces angiogenesis and VEGF expression.